Antimicrobial Resistance Cost in Two Ghanaian Hospitals

By Staff Writer

January 8, 2024

Antimicrobial Resistance Costs: A Burden on Healthcare Providers

Antimicrobial resistance (AMR) and antimicrobial resistance costs are a global challenge with significant implications for healthcare providers. A recent study conducted in two public tertiary hospitals in Ghana, a lower-middle-income setting, quantified the healthcare provider costs (HPCs) due to AMR using both aggregated ingredient costing and step-down costing approaches. The results reveal that AMR patients demand more time and resources from healthcare providers than patients infected with susceptible bacteria or uninfected patients.

The Direct Impact of AMR on Hospitals

The study found that if AMR could be avoided, the extra 5 bed days allocated for treating an estimated 740 AMR patients annually at both hospitals would free up 3700 bed days, allowing for the admission of an additional 451 patients. Moreover, doctors spend an extra 7 hours at Hospital 1 and 3 hours at Hospital 2 caring for each AMR patient admitted to the hospital within a 30-day data collection period.

The Cost of AMR

The research also highlighted the variation in costs due to AMR causative pathogens. For instance, treating each patient with MRSA bloodstream infections at Hospital 1 was approximately 33% higher than treating K. pneumoniae and 16% higher than E. coli bloodstream infections resistant to 3GC. The provider cost of treating AMR was highest for the medical emergency unit due to its limited capacity to treat patients with severe and emergency health conditions compared to the general medical unit.

Mitigating AMR: A Matter of Urgency

The findings underscore the urgent need for healthcare providers and policymakers to focus on AMR mitigation measures. Such measures may include general infection prevention and control, effective antibiotic regulation, and adherence to WHO’s access, watch and reserve (AWaRe) recommendation for antibiotic prescription and therapy. The study also advocates for demand-driven strategies, such as point-of-care education regarding antibiotic use and resistance’s health and economic implications, and supply-driven interventions like hospital-wide antibiotic restriction policy implementation.

In conclusion, AMR imposes significant costs on healthcare providers, particularly in lower-middle-income settings. These costs can be avoided through a myriad of infection prevention and control strategies, thus making a strong case for investment in AMR mitigation strategies.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.